Associations of Serum Long-Chain Fatty Acids with Multiple Organ Involvements in Patients with Sarcoidosis

doi:10.21203/rs.3.rs-1433676/v1

Download PDF

Research Article

Associations of Serum Long-Chain Fatty Acids with Multiple Organ Involvements in Patients with Sarcoidosis

https://doi.org/10.21203/rs.3.rs-1433676/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Background

Fatty acids have diverse immunomodulatory functions and the potential to be associated with inflammatory responses in sarcoidosis.

Methods

The serum levels of multiple long-chain fatty acids (LCFAs) were compared between 63 patients with sarcoidosis and 38 healthy controls. The associations of LCFAs with clinical outcomes of sarcoidosis were also evaluated.

Results

The patients with sarcoidosis had significantly lower levels of n-3 poly-unsaturated fatty acids (PUFAs) (p < 0.001) and n-6 PUFAs (p < 0.001) than the healthy controls. However, there were no significant differences in the levels of saturated fatty acids (SFAs) and mono-unsaturated fatty acids (MUFAs) between the two groups. On multivariate logistic analysis, lower levels of n-3 PUFAs, n-6 PUFAs, and n-3/n-6 ratio were predictive of sarcoidosis. Among the patients with sarcoidosis, those with multiple organ involvement had significantly lower levels of n-3 PUFAs and n-3/n-6 ratio than those with single organ involvement. There were no significant differences in the levels of n-6 PUFAs, SFAs, and MUFAs between the patients with multiple and single organ involvement. On multivariate logistic analysis, lower levels of SFAs and n-3/n-6 ratio were predictive of multiple organ involvement. The levels of LCFAs had no significant association with radiographic stage or spontaneous remission.

Conclusions

Assessment of LCFA profiles may be useful for the diagnosis of sarcoidosis and evaluation of the disease activity.

lipid

metabolites

omega-3 fatty acids

omega-6 fatty acids

immune metabolism

Sarcoidosis is a systemic granulomatous disease that affects multiple organs and lymphatic systems throughout the body [1]. It is widely considered to be a benign disease, and spontaneous remission occurs in about two-thirds of patients. However, patients with progressive pulmonary disease, central nerve, or heart involvement have a poor prognosis [1][2]. Although the precise mechanism remains unknown, sarcoidosis is thought to result from a systemic inflammatory disorder involving Th1 immune responses [1][3]. Recent evidence supports the notion that sarcoidosis involves complex interplay among diverse immune cells [3].

It has become increasingly clear that metabolites derived from nutrients like glucose, amino acids, and fatty acids play essential roles in the control of immunity. Fatty acids not only serve as energy resources and cell membrane components, but also act for activation of immune cells, including effector T cells, natural killer T cells, macrophages, and dendritic cells [4][5][6][7][8][9]. Fatty acids are divided into several groups based on common molecular structures and specific immunomodulatory properties. For example, lipid mediators derived from n-6 polyunsaturated fatty acids (PUFAs), such as prostaglandin D₂ (PGD₂), PGE₂, and leukotriene B4 (LTB₄), have pro-inflammatory properties, while lipid mediators derived from n-3 PUFAs, such as maresins and resolvins, have anti-inflammatory properties [10][11]. Furthermore, saturated fatty acids (SFAs) can induce polarization of naïve T cells toward Th1 and Th17 cells [12][13], activate bone marrow-derived dendritic cells, and increase T cell activation capacity [14].

Because of their immunomodulatory roles, fatty acids have attracted attention as the pathogenesis and/or potential treatment targets in several inflammatory diseases. For example, patients with chronic obstructive pulmonary disease (COPD) had lower levels of n-3 PUFAs in their sputum than healthy controls [15]. In addition, higher levels of n-6 PUFAs were observed during acute exacerbation of COPD compared with stable COPD [15]. Furthermore, patients with idiopathic pulmonary fibrosis had higher levels of SFAs in their bronchoalveolar lavage fluid than healthy controls [16]. Meanwhile, epidemiological data indicated a beneficial effect of n-3 PUFAs for prevention of ulcerative colitis, while consumption of a lower ratio of n-3 PUFAs to n-6 PUFAs was associated with an increased risk of ulcerative colitis [17].

Nevertheless, little is known about the fatty acid profiles in patients with sarcoidosis. Given the diverse immunomodulatory functions of fatty acids and their associations with several inflammatory diseases, we hypothesized that altered profiles of fatty acids are associated with sarcoidosis and disease severity. In the present study, we compared the serum levels of multiple fatty acids between patients with sarcoidosis and healthy controls. We also evaluated the associations of fatty acid levels with disease severity and clinical outcomes of sarcoidosis.

Participants

This retrospective observational study was conducted in accordance with the ethical standards of the Declaration of Helsinki. Consecutive patients with sarcoidosis diagnosed between May 1998 and December 2019 at Hamamatsu University Hospital were included. The diagnosis of sarcoidosis was based on the consensus statement of the American Thoracic Society, the European Respiratory Society, and the World Association of Sarcoidosis and Other Granulomatous Disorders [1]. Eligible patients were required to have available serum samples at diagnosis. The requirement for informed consent from the patients was waived because of the retrospective nature of the study. Healthy volunteers without sarcoidosis were evaluated as controls. The study was approved by the Institutional Review Board of Hamamatsu University School of Medicine (No. 20-228).

Data collection

Clinical data at diagnosis, including age, sex, body mass index (BMI), smoking status, affected organs, laboratory parameters, radiographic data, pulmonary function tests, bronchoalveolar lavage (BAL), pathological information, and affected organs, were retrospectively evaluated using medical records. Radiographic stage was evaluated according to the consensus statement of the American Thoracic Society, the European Respiratory Society and the World Association of Sarcoidosis and Other Granulomatous Diseases [1]. Treatments and clinical courses were also evaluated during the study period. For the healthy controls, age, sex, BMI, and smoking status were evaluated.

LCFA measurements

Multiple LCFAs were evaluated using serum samples at the time of diagnosis. Twenty-four LCFAs were evaluated by gas chromatography (GC-2010; Shimadzu, Kyoto, Japan) as follows: (1) n-3 PUFAs = linolenic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid; (2) n-6 PUFAs = linoleic acid, γ-linolenic acid, eicosadienoic acid, dihomo-γ-linolenic acid, arachidonic acid, docosatetraenoic acid; (3) SFAs = lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid; and (4) monounsaturated fatty acids (MUFAs) = myristoleic acid, palmitoleic acid, oleic acid, eicosenoic acid, eicosatrienoic acid, erucic acid, nervonic acid. Erucic acid was excluded from the analysis because its levels were below the measurement sensitivity in most patients. The levels of the LCFAs were evaluated separately and together in each category. The ratio of n-3 and n-6 PUFAs (n-3/n-6 ratio) was also calculated to evaluate the balance of these PUFAs. All LCFAs were measured at a laboratory (SRL Inc., Tokyo, Japan) certified by the College of American Pathologists and International Organization for Standardization 15189.

Statistical analyses

The Mann–Whitney U-test and Fisher’s exact test were used for comparisons of continuous and categorical variables, respectively. Correlations between LCFA levels and clinical data were assessed using Spearman’s rank correlation coefficient. Receiver operating characteristic curve analyses were conducted to determine cutoff values for LCFA levels using the Youden Index (maximum value of [sensitivity + specificity − 1]) (Supplementary Tables 1 and 2). Logistic regression analyses were carried out to evaluate predictive factors for the diagnosis of sarcoidosis and multiple organ involvement. Age, sex, and variables with P<0.100 in univariate analyses were employed for multivariate analyses. When variables had strong correlations with one another (Spearman’s correlation coefficient >0.7), only one was selected for multivariate analysis to avoid multicollinearity. Candidate combinations for multivariate analysis were created using LCFAs without strong correlations with one another. Akaike information criteria were used to obtain estimated prediction errors for the multivariate analyses. Statistical analyses were performed using EZR software (version 1.41; Saitama Medical Center, Jichi Medical University, Saitama, Japan). Values of P<0.05 were considered statistically significant.

Patient characteristics

A total of 150 patients with sarcoidosis were screened, of whom 87 were excluded because they lacked assessable serum samples at diagnosis (n = 83) or had insufficient available data (n = 4). As a result, 63 patients with sarcoidosis were included in the study (Fig. 1). The patient characteristics are shown in Table 1. The median age was 58 years (interquartile range [IQR], 45–68 years) and 38 (60.3%) patients were female. The most frequently affected organs were the lungs (98.4%), followed by the eyes (52.4%), skin (15.9%), and heart (6.3%). Forty-five (71.4%) patients had two or more affected organs. On chest X-rays, 21 (33.3%), 40 (63.5%), and 36 (57.1%) patients had bilateral hilar lymphadenopathy (BHL), lung parenchymal involvement, or both, respectively. Among 61 patients who underwent pulmonary function tests, 55 (90.2%) had normal pulmonary function (forced vital capacity, % predicted [%FVC] ≥ 80.0). The median observation time was 5.5 years (IQR, 4.0–10.3 years). The 38 healthy controls had a median age of 34 years (IQR, 27–43 years), a median BMI of 22.2 kg/m² (IQR, 19.6–23.7 kg/m²), a female proportion of 39.5%, and no smoking history (Supplementary Table 3). The healthy controls were significantly younger and had a lower proportion of smoking history than the patients with sarcoidosis (both p < 0.001)

Table 1

Patient characteristics
	All patients n = 63	Single organ involvement, n = 18	Multiple organ involvement n = 45	P-value*
Age, years	58 (45–68)	59 (44–75)	57 (45–65)	0.330
Sex, female	38 (60.3)	9 (50.0)	29 (64.4)	0.394
Body mass index, kg/m²	21.4 (20.1–23.8)	21.9 (20.4–23.1)	21.4 (19.9–23.8)	0.897
Smoking, ever-smoker	31 (49.2)	9 (50.0)	22 (48.9)	1.000
Number of affected organs, 1/2/3/4/5	18/30/13/1/1	18/0/0/0/0	0/30/13/1/1	< 0.001
Affected organs
Lungs^a	62 (98.4)	17 (94.4)	45 (100.0)	0.286
Eyes	33 (52.4)	1 (5.6)	32 (71.1)	< 0.001
Skin	10 (15.9)	0	10 (22.2)	0.051
Heart	4 (6.3)	0	4 (8.9)	0.317
Others^b	13 (20.6)	0	13 (28.9)	0.013
Serum ACE, IU/L	19.3 (14.5–25.3)	16.6 (14.2–21.5)	21.4 (15.1–25.4)	0.122
Radiographic stage, 0/Ⅰ/Ⅱ/Ⅲ/Ⅳ	1/21/36/4/1	1/6/9/1/1	0/15/27/3/0	0.802
Pulmonary function tests (n = 61)
FVC, L	2.76 (2.34–3.40)	3.00 (2.43–3.49)	2.75 (2.33–3.30)	0.389
FVC, % predicted	94.9 (88.1-100.7)	96.4 (90.8-104.9)	94.1 (87.5-100.3)	0.187
FEV₁, L	2.10 (1.82–2.79)	2.55 (1.92–3.36)	2.10 (1.81–2.66)	0.385
FEV₁, % predicted	90.3 (77.4-100.2)	89.5 (78.2–98.8)	91.1 (76.1-100.5)	0.915
FEV₁/FVC, %	77.9 (74.3–83.8)	78.2 (74.8–82.8)	77.9 (72.9–85.1)	0.812
Bronchoalveolar lavage (n = 62)
Total cells, ×10⁵/ml	0.96 (0.61–1.48)	1.00 (0.51–1.51)	0.93 (0.68–1.47)	0.561
Lymphocytes, %	11.9 (8.2–22.9)	19.0 (5.9–26.5)	11.5 (8.3–19.9)	0.852
CD4/CD8 ratio	5.02 (3.30–7.75)	4.58 (3.30–6.49)	5.16 (3.34–7.91)	0.841
Data are presented as median (interquartile range) or number (%).
ACE, angiotensin-converting enzyme; FVC, forced vital capacity; FEV₁, forced expiratory volume in 1 second.
Radiographic stages 0, Ⅰ, Ⅱ, Ⅲ, and Ⅳ represent normal appearance, bilateral hilar lymphadenopathy (BHL) alone, BHL and lung parenchymal involvement, lung parenchymal involvement without BHL, and pulmonary fibrosis, respectively.
^aLungs include pulmonary hilar and mediastinal lymphadenopathy.
^bOthers include muscle, liver, thyroid gland, spleen, nerve, and extramediastinal lymphadenopathy.
*Comparison between patients with single and multiple organ involvement.

Clinical Outcomes Of Patients With Sarcoidosis

Eight (12.7%) patients received treatment for sarcoidosis from the time of diagnosis, comprising 7 with corticosteroid alone and 1 with a combination of corticosteroid plus azathioprine. After the treatment, 2 had remission, 2 had stable disease, and 4 had disease progression (Fig. 1). The remaining 55 patients were initially followed without treatment, of whom 20 (36.4%) had spontaneous remission, 25 (45.5%) had stable disease, 6 (10.9%) had disease progression, and 4 (7.3%) were lost to follow-up during the observation period (Fig. 1). Among 6 patients with disease progression after the initial follow-up, 2 (33.3%), 3 (50.0%), and 1 (16.7%) had worsening of lung involvement, development of non-pulmonary lesions, and both, respectively, with 5 receiving corticosteroid alone and 1 receiving no treatment. Among the 5 patients who received corticosteroid, 4 had remission, but 1 had disease progression. One patient who did not receive treatment after disease progression did not deteriorate further or require any treatment.

Associations Of Lcfa Levels With Demographic Characteristics

Among the 63 patients with sarcoidosis, there were weak or moderate correlations between age and n-3 PUFAs (r = 0.35) or n-3/n-6 ratio (r = 0.49), and between BMI and MUFAs (r = 0.25) (Supplementary Fig. 1). The LCFA levels were not correlated with sex (Supplementary Table 4). Among the LCFAs, there were strong correlations between n-3 PUFAs and n-6 PUFAs (r = 0.80), and between SFAs and MUFAs (r = 0.92). The correlations among single LCFAs are presented in Supplementary Fig. 2.

Comparisons Of Serum Lcfa Levels Between Patients With Sarcoidosis And Healthy Controls

The patients with sarcoidosis had significantly lower levels of n-3 PUFAs (p < 0.001) and n-6 PUFAs (p < 0.001) than the healthy controls (Fig. 2A, B). When the LCFAs were evaluated separately, the levels of all n-3 PUFAs (linolenic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid) were significantly lower in the patients with sarcoidosis (p < 0.001 for all) (Supplementary Fig. 3). Likewise, the levels of all n-6 PUFAs other than eicosadienoic acid (linoleic acid, γ-linolenic acid, dihomo-γ-linolenic acid, arachidonic acid, docosatetraenoic acid) were significantly lower in the patients with sarcoidosis (p < 0.001, p = 0.016, p = 0.007, p < 0.001, and p < 0.001, respectively) (Supplementary Fig. 3). However, there were no significant differences in the levels of n-3/n-6 ratio, SFAs, and MUFAs between the two groups (Fig. 2C–E). Furthermore, the levels of myristic acid (p = 0.004), myristoleic acid (p < 0.001), and palmitoleic acid (p < 0.001) were significantly higher in the patients with sarcoidosis, while the levels of other SFAs and MUFAs did not differ between the two groups (Supplementary Fig. 3).

On univariate logistic analysis, higher levels of MUFAs and lower levels of n-3 PUFAs, n-6 PUFAs, and n-3/n-6 ratio were predictive of sarcoidosis, as were age and sex (Table 2). On multivariate logistic analysis, lower levels of n-3 PUFAs, n-6 PUFAs, and n-3/n-6 ratio were predictive of sarcoidosis, as was age (Table 2). When the LCFAs were evaluated separately, higher levels of myristic acid, myristoleic acid, palmitoleic acid, and eicosenoic acid, and lower levels of arachidic acid, behenic acid, linolenic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, linoleic acid, γ-linolenic acid, dihomo-γ-linolenic acid, arachidonic acid, and docosatetraenoic acid were predictive of sarcoidosis on univariate logistic analysis (Supplementary Table 5). After adjustment by age and sex, higher levels of myristoleic acid and palmitoleic acid, and lower levels of stearic acid, arachidic acid, behenic acid, lignoceric acid, linolenic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, linoleic acid, γ-linolenic acid, dihomo-γ-linolenic acid, arachidonic acid, and docosatetraenoic acid were independently predictive of sarcoidosis (Supplementary Table 5).

Table 2

Logistic regression analyses for the diagnosis of sarcoidosis
	Univariate analysis		Multivariate analysis
	Univariate analysis		Set A		Set B		Set C
Variables	OR (95%CI)	P-value	OR (95%CI)	P-value	OR (95%CI)	P-value	OR (95%CI)	P-value
Age^a	1.11 (1.06–1.16)	< 0.001	1.20 (1.10–1.31)	< 0.001	1.11 (1.05–1.18)	< 0.001	1.11 (1.06–1.16)	< 0.001
Sex, male	0.43 (0.19–0.98)	0.044	2.66 (0.44–16.30)	0.289	1.64 (0.38–7.01)	0.505	0.81 (0.26–2.59)	0.727
BMI^b	0.97 (0.83–1.13)	0.671
n-3 PUFAs, high	0.05 (0.01–0.18)	< 0.001	0.01 (0.00-0.05)	< 0.001
n-6 PUFAs, high	0.06 (0.02–0.19)	< 0.001			0.03 (0.01–0.14)	< 0.001
n-3/n-6 ratio, high	0.34 (0.13–0.90)	0.030					0.25 (0.07–0.83)	0.023
SFAs, high	2.18 (0.85–5.61)	0.105
MUFAs, high	3.26 (1.14–9.34)	0.028	1.13 (0.15–8.71)	0.906	4.27 (0.87-21.00)	0.074	1.59 (0.38–6.58)	0.526
The cutoff value for each long-chain fatty acid was determined by the Youden Index in receiver operating characteristic curve analysis (Supplementary Table 1). The Akaike Information criteria for Sets A, B, and C were 58.6, 76.1, and 96.4, respectively. OR, odds ratio; CI, confidence interval; BMI, body mass index; SFAs, saturated fatty acids; PUFAs, polyunsaturated fatty acids; MUFAs, monounsaturated fatty acids.
^aPer 1-year increase.
^bPer 1-kg/m² increase.

Associations Of Serum Lcfa Levels With Multiple Organ Involvement In Patients With Sarcoidosis

Among the patients with sarcoidosis, those with multiple organ involvement had significantly lower levels of n-3 PUFAs and n-3/n-6 ratio than those with single organ involvement (Fig. 2A, C). When the LCFAs were evaluated separately, the levels of all n-3 PUFAs except linolenic acid (eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid) were significantly lower in the patients with multiple organ involvement (p = 0.032, p = 0.021, and p = 0.033, respectively) (Supplementary Fig. 3). Meanwhile, there were no significant differences in the levels of n-6 PUFAs, SFAs, and MUFAs between the patients with multiple and single organ involvement (Fig. 2B, D, E).

On univariate logistic analysis, lower levels of SFAs, n-3 PUFAs, n-6 PUFAs, and n-3/n-6 ratio were predictive of multiple organ involvement (Table 3). On multivariate logistic analysis, lower levels of SFAs and n-3/n-6 ratio were predictive of multiple organ involvement (Table 3). When the LCFAs were evaluated separately, lower levels of palmitic acid, stearic acid, palmitoleic acid, eicosatrienoic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, linoleic acid, γ-linolenic acid, and dihomo-γ-linolenic acid were predictive of multiple organ involvement on univariate logistic analysis, (Supplementary Table 6). After adjustment by age, sex, and serum angiotensin converting enzyme level, lower levels of palmitoleic acid, eicosatrienoic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, γ-linolenic acid, and dihomo-γ-linolenic acid were independently predictive of multiple organ involvement (Supplementary Table 6).

Table 3

Logistic regression analyses for multiple organ involvement in sarcoidosis
	Univariate analysis		Multivariate analysis
	Univariate analysis		Set 1		Set 2		Set 3
Variables	OR (95%CI)	P-value	OR (95%CI)	P-value	OR (95%CI)	P-value	OR (95%CI)	P-value
Age^a	0.98 (0.95–1.02)	0.339	0.99 (0.94–1.04)	0.716	0.98 (0.93–1.02)	0.300	1.01 (0.95–1.06)	0.815
Sex, male	0.55 (0.18–1.67)	0.293	0.64 (0.15–2.67)	0.537	0.53 (0.13–2.19)	0.383	0.72 (0.16–3.25)	0.664
BMI^b	1.01 (0.82–1.25)	0.930
Serum ACE, ≥ 21.4 IU/L	1.08 (0.99–1.18)	0.096	2.41 (0.64–9.14))	0.196	2.40 (0.64–9.03)	0.195	2.53 (0.62–10.30)	0.195
Radiographic stage, ≥ Ⅱ	1.27 (0.41–3.95)	0.676
Pulmonary function test
FVC % predicted^c	0.97 (0.93–1.02)	0.240
FEV1/FVC^c	1.00 (0.98–1.01)	0.692
Bronchoalveolar lavage
Lymphocytes^c	1.01 (0.97–1.04)	0.767
CD4/CD8 ratio, ≥ 3.5	0.99 (0.29–3.39)	0.992
n-3 PUFAs, high	0.23 (0.07–0.74)	0.013	0.33 (0.09–1.24)	0.101
n-6 PUFAs, high	0.30 (0.09–1.05)	0.059			0.43 (0.11–1.67)	0.225
n-3/n-6 ratio, high	0.16 (0.05–0.53)	0.003					0.14 (0.03–0.61)	0.009
SFAs, high	0.16 (0.03–0.76)	0.022	0.25 (0.05–1.35)	0.107	0.25 (0.05–1.34)	0.105	0.16 (0.03–0.96)	0.045
MUFAs, high	1.00 (0.18–5.69)	1.000
The cutoff value for each long-chain fatty acid was determined by the Youden Index in receiver operating characteristic curve analysis (Supplementary Table 2). The Akaike Information criteria for Sets 1, 2, and 3 were 74.1, 75.4, and 69.1, respectively. OR, odds ratio; CI, confidence interval; BMI, body mass index; ACE, angiotensin-converting enzyme; FVC, forced vital capacity; FEV₁, forced expiratory volume in 1 second; SFAs, saturated fatty acids; PUFAs, polyunsaturated fatty acids; MUFAs, monounsaturated fatty acids.
^aPer 1-year increase.
^bPer 1-kg/m² increase.
^cPer 1% increase.

Associations Of Serum Lcfa Levels With Other Outcomes In Patients With Sarcoidosis

There were no significant associations between lung parenchymal involvement (radiographic stage ≥ 2) and n-3 PUFAs, n-6 PUFAs, n-3/n-6 ratio, SFAs, or MUFAs (Supplementary Fig. 4). Among 51 patients who were followed up without treatment, there were no significant associations between disease progression and n-3 PUFAs, n-6 PUFAs, n-3/n-6 ratio, SFAs, or MUFAs (Supplementary Fig. 5).

In the present study, we found that patients with sarcoidosis had lower levels of n-3 PUFAs, n-6 PUFAs, and n-3/n-6 ratio than healthy controls. Furthermore, among the patients with sarcoidosis, lower levels of SFAs and n-3/n-6 ratio were associated with multiple organ involvement. Our data indicated that distinctive LCFA profiles were associated with sarcoidosis.

It is well-known that n-3 PUFAs have anti-inflammatory effects via several immune cells. For example, n-3 PUFAs prevented differentiation and activation of CD4⁺ T cells, a key component of sarcoidosis [10]. Incorporation of n-3 PUFAs induced changes in membrane domain organization, which could account for the alterations in CD4⁺ T cell function [18][19]. In addition, n-3 PUFAs were reported to blunt M1 macrophage polarization and promote M2 polarization by decreasing the secretion of Th1 cytokines [10]. Meanwhile, n-3 PUFAs attenuate the differentiation and activation of Th17 cells, which are recognized to play important roles in the pathogenesis of sarcoidosis. Several studies demonstrated that addition of n-3 PUFAs resulted in a decrease in Th17 differentiation from CD4⁺ T cells [20][21]. Possible mechanisms include failure of CD4⁺ T cells to activate Stat-3 in response to pro-TH17 signals under high levels of n-3 PUFAs [22][23]. Meanwhile, supplementation of n-3 PUFAs promoted the accumulation and proliferation of regulatory T cells (Tregs) in mouse models [24][25][26]. Furthermore, n-3 PUFAs were shown to increase M2 macrophages, thereby inducing Treg differentiation [24][27]. Given the anti-inflammatory roles of n-3 PUFAs, it is possible that the decreased levels of n-3 PUFAs promote immune cell activation, thus facilitating the development of sarcoidosis.

Meanwhile, the association of sarcoidosis with n-6 PUFAs is not easy to explain. This is because that n-6 PUFAs can play pro-inflammatory or anti-inflammatory roles, depending on the types of lipid mediators, receptors, and target immune cells [11]. For example, PGE₂, a representative lipid mediator derived from n-6 PUFAs, promoted inflammation via EP2 receptors on neutrophils and tumor-associated fibroblasts [28]. However, PGE₂ signaling via EP4 receptors had anti-inflammatory roles by regulating Th1 cytokine production in a colitis model [29]. Similarly, leukotriene B4 (LTB₄), another important lipid mediator derived from n-6 PUFAs, promoted the production of inflammatory cytokines by stimulating BTL1 receptors on dendritic cells, but suppressed the production of inflammatory cytokines by stimulating BLT2 receptors on cryptic cells in colitis models [30][31]. Although the precise roles of n-6 PUFAs for sarcoidosis are unknown, it is possible that the decreased levels of n-6 PUFAs indicate attenuated anti-inflammatory properties.

When considering immunomodulatory roles of LCFAs, the balance between n-3 and n-6 PUFAs is also important. The anti-inflammatory properties of n-3 PUFAs are accomplished by competing against n-6 PUFAs. Lipid mediators derived from n-3 and n-6 PUFAs are orchestrated by cyclooxygenase, lipoxygenase, or cytochrome p450 enzymes [32]. In the presence of n-3 PUFAs, the competition for the enzymes reduces the synthesis of n-6 PUFAs. Therefore, the balance between n-3 and n-6 PUFAs, expressed as the n-3/n-6 ratio, is considered to be an index of inflammation. The lower level of n-3/n-6 ratio in the patients with sarcoidosis and the multiple organ involvement in the present study may indicate an increased pro-inflammatory status in these patients.

The potential mechanisms for the effects of SFAs on immune systems were reported to include protection from pathogenic microorganisms possibly by activating the Toll-like receptor 4 signaling pathway [33]. Therefore, lower levels of SFAs were associated with poor outcomes in infectious diseases, while supplementation of SFAs improved these outcomes [34][35][36][37]. Although controversy exists, several microorganisms are supposed to be associated with sarcoidosis [1]. We speculate that attenuated anti-microorganism activity due to the decreased levels of SFAs may be associated with the multiple organ involvement in patients with sarcoidosis.

There are two major limitations to the present study. First, it is unknown whether the differences in LCFA levels were associated with the development and/or disease activity of sarcoidosis, or merely resulted from deterioration of the nutritional status due to sarcoidosis. Second, the differences in biological activities among the individual LCFAs are unknown. Usually, single LCFAs in the same family are considered to have similar biological activities; however, the precise differences among those LCFAs have not been fully investigated (for example, among linolenic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid in the n-3 PUFAs). In fact, LCFAs in the same family were strongly associated with one another, and therefore had similar associations with sarcoidosis and/or multiple organ involvement. However, at the same time, some LCFAs were weakly associated with other LCFAs in the same family, and demonstrated different associations with sarcoidosis and/or multiple organ involvement. Further studies are needed to elucidate the mechanisms and clinical significance of LCFAs for sarcoidosis.

Lower levels of n-3 PUFAs, n-6 PUFAs, and n-3/n-6 ratio were associated with sarcoidosis, and lower levels of SFAs and n-3/n-6 ratio were associated with multiple organ involvement. Assessment of LCFA profiles may be useful for the diagnosis of sarcoidosis and evaluation of the disease activity.

Ethics approval and consent to participate: This study was conducted in accordance with the ethical standards of the Declaration of Helsinki.　The study protocol was approved by the Institutional Review Board of Hamamatsu University School of Medicine (No. 20-228). Patient consent was waved because this was a retrospective study.

Consent for publication: Not applicable

Availability of data and material: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests: All authors have no conflict of interest in relation to this manuscript.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors’ contributions:

MK has full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. TS participated in study concept and design; acquisition, analysis and interpretation of data; statistical analyses; and drafting of the manuscript. YI, HH, YS, KF, TF, NE, and YN participated in study concept and design, interpretation of data, and drafting of the manuscript. NI and TS participated in study concept and design, drafting of the manuscript, and supervision.

Acknowledgments

The authors thank Alison Sherwin, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ER. Am J Respir Crit Care Med. 1999;160:736–55. http://www.ncbi.nlm.nih.gov/pubmed/10670511.
Thillai M, Atkins CP, Crawshaw A, Hart SP, Ho LP, Kouranos V, et al. BTS Clinical Statement on pulmonary sarcoidosis. Thorax. 2021;76:4–20.
Zhang H, Costabel U, Dai H. The Role of Diverse Immune Cells in Sarcoidosis. Front Immunol. 2021;12 November:1–10.
Erika L. Pearce, Edward J. Pearce. Metabolic pathways in immune cell activation and quiescence. Immunity. 2013;38:633–43.
Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: Energy metabolism and the T-cell response. Nat Rev Immunol. 2005;5:844–52.
Kishton RJ, Sukumar M, Restifo NP. Metabolic regulation of T cell longevity and function in tumor immunotherapy. Cell Metab. 2017;26:94–109.
O’Brien KL, Finlay DK. Immunometabolism and natural killer cell responses. Nat Rev Immunol. 2019;19:282–90.
Newton R, Priyadharshini B, Turka LA. Immunometabolism of regulatory T cells. Nat Immunol. 2016;17:618–25.
Lochner M, Berod L, Sparwasser T. Fatty acid metabolism in the regulation of T cell function. Trends Immunol. 2015;36:81–91.
Gutiérrez S, Svahn SL, Johansson ME. Effects of omega-3 fatty acids on immune cells. Int J Mol Sci. 2019;20.
Nagatake T, Kunisawa J. Emerging roles of metabolites of ω3 and ω6 essential fatty acids in the control of intestinal inflammation. Int Immunol. 2019;31:569–77.
Haghikia A, Jörg S, Duscha A, Berg J, Manzel A, Waschbisch A, et al. Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. Immunity. 2015;43:817–29.
Hammer A, Schliep A, Jörg S, Haghikia A, Gold R, Kleinewietfeld M, et al. Impact of combined sodium chloride and saturated long-chain fatty acid challenge on the differentiation of T helper cells in neuroinflammation. J Neuroinflammation. 2017;14:1–9.
Weatherill AR, Lee JY, Zhao L, Lemay DG, Youn HS, Hwang DH. Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. J Immunol. 2005;174:5390–7.
van der Does AM, Heijink M, Mayboroda OA, Persson LJ, Aanerud M, Bakke P, et al. Dynamic differences in dietary polyunsaturated fatty acid metabolism in sputum of COPD patients and controls. Biochim Biophys Acta - Mol Cell Biol Lipids. 2019;1864:224–33. doi:10.1016/j.bbalip.2018.11.012.
Chu SG, Villalba JA, Liang X, Xiong K, Tsoyi K, Ith B, et al. Palmitic acid-rich high-fat diet exacerbates experimental pulmonary fibrosis by modulating endoplasmic reticulum stress. Am J Respir Cell Mol Biol. 2019;61:737–46.
Scaioli E, Liverani E, Belluzzi A. The imbalance between N-6/N-3 polyunsaturated fatty acids and inflammatory bowel disease: A comprehensive review and future therapeutic perspectives. Int J Mol Sci. 2017;18.
Hou TY, Rola Barhoumid, Fan Y-Y, Rivera GM, Hannoush RN, McMurray DN, et al. n-3 polyunsaturated fatty acids suppress CD4 + T cell proliferation by altering phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2] organization. Biochim Et Biophys Acta-Biomembr. 2016;1858:85–96.
Fan Y-Y, Natividad R. Fuentes, Hou TY, Barhoumi R, Li XC, Deutz NEP, et al. Remodelling of primary human CD4 + T cell plasma membrane order by n-3 PUFA. Br J Nutr. 2018;119:139-163-75.
Chiurchiù V, Alessandro Leuti, Dalli J, Jacobsson A, Battistini L, Maccarrone M, et al. Pro-resolving lipid mediators Resolvin D1, Resolvin D2 and Maresin 1 are critical in modulating T cell responses. Sci Transl Med. 2016;8:353ra111.
Jeffery L, Fisk HL, Calder PC, Filer A, Raza K, Buckley CD, et al. Plasma levels of eicosapentaenoic acid are associated with anti-TNF responsiveness in rheumatoid arthritis and inhibit the etanercept-driven rise in Th17 cell differentiation in vitro. J Rheumatol. 2017;44:748–56.
Monk JM, Hou TY, Turk HF, McMurray DN, Chapkin RS. n3 PUFAs reduce mouse CD4 + T-Cell ex vivo polarization into Th17 Cells. J Nutr. 2013;143:1501–8.
Allen MJ, Fan YY, Monk JM, Hou TY, Barhoumi R, McMurray DN, et al. n-3 PUFAs reduce T-helper 17 cell differentiation by decreasing responsiveness to interleukin-6 in isolated mouse splenic CD4 + T cells. J Nutr. 2014;144:1306–13.
Onodera T, Fukuhara A, Shin J, Hayakawa T, Otsuki M, Shimomura I. Eicosapentaenoic acid and 5-HEPE enhance macrophage-mediated Treg induction in mice. Sci Rep. 2017;7:1–11.
Lian M, Luo W, Sui Y, Li Z, Hua J. Dietary n-3 PUFA protects mice from Con a induced liver injury by modulating regulatory T cells and PPAR-γ expression. PLoS One. 2015;10:1–16.
Woodworth HL, McCaskey SJ, Duriancik DM, Clinthorne JF, Langohr IM, Gardner EM, et al. Dietary fish oil alters T lymphocyte cell populations and exacerbates disease in a mouse model of inflammatory colitis. Cancer Res. 2010;70:7960–9.
Han SC, Koo DH, Kang NJ, Yoon WJ, Kang GJ, Kang HK, et al. Docosahexaenoic acid alleviates atopic dermatitis by generating tregs and IL-10/TGF-β-modified macrophages via a TGF-β-dependent mechanism. J Invest Dermatol. 2015;135:1556–64. doi:10.1038/jid.2014.488.
Aoki T, Narumiya S. Prostaglandin E2-EP2 signaling as a node of chronic inflammation in the colon tumor microenvironment. Inflamm Regen. 2017;37:1–5. doi:10.1186/s41232-017-0036-7.
Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002;109:883–93.
Maj T, Wang W, Crespo J, Zhang H, Wang W, Zhao L, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol. 2018;18:1332–41.
Iizuka Y, Okuno T, Saeki K, Uozaki H, Okada S, Misaka T, et al. Protective role of the leukotriene B 4 receptor BLT2 in murine inflammatory colitis. FASEB J. 2010;24:4678–90.
Schwanke RC, Marcon R, Bento AF, Calixto JB. EPA- and DHA-derived resolvins’ actions in inflammatory bowel disease. Eur J Pharmacol. 2016;785:156–64. doi:10.1016/j.ejphar.2015.08.050.
Zhang RN, Pan Q, Zhang Z, Cao HX, Shen F, Fan JG. Saturated fatty acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic fatty liver disease by toll-like receptor 4-mediated innate immune response. Hepat Mon. 2015;15.
Wang L, Johnson EA. InhibitionofListeriamonocytogenes byFattyAcids and Monoglycerides. Appl Env Microbiol. 1992;58:624–9.
Kitahara T, Koyama N, Matsuda J, Aoyama Y, Hirakata Y, Kamihira S, et al. Antimicrobial activity of saturated fatty acids and fatty amines against methicillin-resistant Staphylococcus aureus. Biol Pharm Bull. 2004;27:1321–6.
Dingwoke EJ, Adamude FA, Chukwuocha CE, Ambi AA, Nwobodo NN, Sallau AB, et al. Inhibition of trypanosoma evansi protein-tyrosine phosphatase by myristic acid analogues isolated from khaya senegalensis and tamarindus indica. J Exp Pharmacol. 2019;11:135–48.
Fischer CL, Drake DR, Dawson D V., Blanchette DR, Brogden KA, Wertz PW. Antibacterial activity of sphingoid bases and fatty acids against gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 2012;56:1157–61.

No competing interests reported.

SupplementaryMaterials.docx

Download PDF

Editorial decision: Major revision
28 Jun, 2022
Reviews received at journal
22 May, 2022
Reviews received at journal
18 May, 2022
Reviewers agreed at journal
13 May, 2022
Reviewers agreed at journal
13 May, 2022
Reviewers invited by journal
06 May, 2022
Editor assigned by journal
06 May, 2022
Editor invited by journal
16 Mar, 2022
Submission checks completed at journal
16 Mar, 2022
First submitted to journal
09 Mar, 2022

You are reading this latest preprint version

Associations of Serum Long-Chain Fatty Acids with Multiple Organ Involvements in Patients with Sarcoidosis

Status:

Version 1

Abstract

Background

Methods

Results

Conclusions

Figures

Introduction

Methods

Results

Patient characteristics

Clinical Outcomes Of Patients With Sarcoidosis

Associations Of Lcfa Levels With Demographic Characteristics

Comparisons Of Serum Lcfa Levels Between Patients With Sarcoidosis And Healthy Controls

Associations Of Serum Lcfa Levels With Multiple Organ Involvement In Patients With Sarcoidosis

Associations Of Serum Lcfa Levels With Other Outcomes In Patients With Sarcoidosis

Discussion

Conclusions

Declarations

References

Additional Declarations

Supplementary Files

Status:

Version 1